AzTrials
AzTrials

Lupus Erythematosus, SystemicEFINUTRILESNCT05261529

Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus

A study testing Extra Virgin Olive Oil (EVOO) and Physical Exercise Program in people with Lupus Erythematosus, Systemic, run by Universidad de Granada at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In addition to the different pharmacological therapies available for the treatment of Systemic Lupus Erythematosus (SLE) as well as for its numerous associated complications (cutaneous, articular, hematological, neuropsychiatric, renal...), it has recently been proposed that 'health-related lifestyles' could have a… Read more about this study

Who is it for?
Ages 18 to 70 years, women only
Conditions the study is for
Lupus Erythematosus, Systemic
What is being tested?
Extra Virgin Olive Oil (EVOO) and Physical Exercise Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteSpain
Study dates
3 Nov 2021to 30 Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Medium (8 to 11 points) to high (12 to 14 points) level of adherence to DM as measured by the 14-point DM adherence scale of the PREDIMED study.
  • Sedentary, inactive or non-performing subjects of structured PE (+5h sitting or doing less than 300min of weekly physical activity or <60min structured exercise per week).

Who cannot join

  • Terminal stages of the disease
  • Serum creatinine levels ≥1.5mg / dl
  • Type 1 Diabetes Mellitus
  • Infection, trauma or surgery six months prior to intervention
  • SLICC> 5
  • Pregnant, with intention, or breastfeeding
Show all 10Show fewer
  • Diagnosis of other autoimmune / inflammatory diseases
  • Participation in other PE guided programs
  • Contraindication for PE: psychiatric or cognitive disorders, acute or chronic conditions (advanced lung disease, high requirements, stenosis> 70%)
  • BMI of morbid obesity (≥40)

Trial locations and contacts

1 site in 1 country.

María Corea Rodríguez, Professor contact

958243494 ext. +34

macoro@ugr.es

Blanca M Rueda Medina, Professor contact

958243494 ext. +34

blarume@ugr.es

Spain1 site, 1 recruiting
  • Universidad de Granada

    Granada, Granada, Spain, 18016

    María Correa Rodríguez, Professor, 958243494 ext. +34, macoro@ugr.es

    Blanca M Rueda Medina, Professor, 958243494 ext. +34, blarume@ugr.es

    Recruiting

Other trials in Spain

About this study

Official title: Effects of a Nutricional Intervention With EVOO Oil and Physical Activity in Patients With Systemic Lupus Erythematosus: Effect on Clinical Course, Epigenetic and Microbiome

In addition to the different pharmacological therapies available for the treatment of Systemic Lupus Erythematosus (SLE) as well as for its numerous associated complications (cutaneous, articular, hematological, neuropsychiatric, renal...), it has recently been proposed that 'health-related lifestyles' could have a determining role in balancing numerous organic processes at all levels. In line with this, the benefits of following a healthy dietary pattern such as the Mediterranean Diet and, specifically, the intake of Extra Virgin Olive Oil (EVOO) as well as the realization of regular physical exercise (PE) have been examined in numerous chronic non-communicable diseases such as obesity or cancer. However, in patients with autoimmune diseases, such as SLE, the possible effects of this synergy has not been investigated to date. Having demonstrated both the protective effect of a healthy dietary pattern and that of regular PE on the progression and risks associated with SLE in cross-sectional studies, non-intervention research has been developed that combines both strategies simultaneously, with nutritional supplementation or PE occurring independently. It is hypothesized that supplementation with EVOO in these patients together with PE will produce superior benefits compared to EVOO supplementation alone, showing changes in the phenotype of SLE and other parameters such as levels of chronicity/gravity, biomarkers (oxidative stress, immunological, inflammation), cardiovascular status and body composition.

Read the detailed description

SLE is one of the more representative autoimmune diseases that courses with several manifestations which are cutaneous-mucosal, joint, hematologic, neuropsychiatric and/or renal. In addition to the different pharmacological therapies available for its treatment, the adequate management of 'health-related lifestyles' becomes a relevant strategy by balancing, among others, the dysbiosis of the microbiota, the production of metabolites and the alteration of the immune response, with positive repercussions on all organic processes. Mediterranean Diet (MD), and the intake of EVOO in specific, which is its most representative food, has been shown to be a proven dietary pattern of protection against chronic non-communicable diseases. In line with this, Physical Exercise (PE) is another strategy on the rise. Regular exercise at moderate intensity has great impact on the immune system, the central nervous system, as a regulator of hormones and blood glucose levels, and on the psychosocial and cognitive spheres, ultimately leading to the appearance of numerous beneficial modifications in the face of external pathogenic aggressions and inflammatory processes.

Therefore, the synergy between DM and PE could enhance the known beneficial effects of both types of approaches in patients with SLE, as the scientific literature has shown in other chronic diseases such as obesity or cancer, among others. However, there are currently few studies that include PE interventions, and there is also some contradiction in the results. In addition, there is no study that synergizes both approaches in a coincident manner over time. The present study, whose main objective is to analyze the influence of the addition to a supplementation with EVOO of a multimodal combined physical exercise intervention in patients with SLE, is developed under the hypothesis that: The combination of dietary supplementation with EVOO together with the follow-up of a multimodal PE program will result in superior benefits in SLE patients with respect to a group of patients solely supplemented with EVOO, showing changes in SLE phenotype and parameters such as levels of chronicity/severity of the disease, levels of biochemical, immunological, inflammatory and oxidative stress markers, markers of cardiovascular risk and early atherosclerosis and endothelial function, cardiorespiratory status and body composition.

For this purpose, a 24-week clinical trial will be developed with three groups of patients with SLE (30 patients/group): a control group (no intervention), another that will add to the usual intake pattern of 40ml of EVOO daily during 24 weeks, and a third group that will add to this additional intake of EVOO the follow-up of a specific PE program in the middle of the intervention (12 weeks).

Data collection in all groups will be perform before the intervention, at an intermediate stage and coinciding with the beginning of the PE program (12 weeks), and at the end of the study (24 weeks).

The study will be carried out in three phases:

STAGE 1: Reinforcement of adherence to DM. In order to guarantee during the intervention the maintenance of the levels of adherence to DM established as inclusion criteria, previously and in both groups the basic principles of DM will be recalled by a nutritionist, through group sessions of 1 hour of duration.

STAGE 2: Intervention. EVOO supplementation, or EVOO supplementation + PE under the conditions previously described. The intervention, which will be extended over 24 weeks, will consist of the daily consumption of 40 ml of EVOO in a single daily intake, added to the usual intake pattern of the participants.

  • CG. The participants' usual lifestyle (dietary pattern and physical activity) will not be modified.
  • Intervention Group 1. Patients will take the EVOO supplementation as describe below, without changing their physical activity routines.
  • Intervention Group 2. In addition to taking EVOO supplementation, patients will start following a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, guided by personnel with experience in the area: 3 days per week, groupal sessions (≤10 participants/group) on non-consecutive days, both online and face-to-face sessions. Continuous (4-6weeks) and intervallic (week 5-7 to 24) cardiovascular exercise will be worked at moderate-intense intensity, controlled by HR in reserve, with a duration of 15-45 minutes. In addition, sympathetic modulation exercises (stretching, breathing, meditation) will be used as methods to promote recovery, with a duration of 10-30 minutes. In this group, supplementation will take place after exertion.

STAGE 3: Post-intervention data collection (week 25).

Being tested
Extra Virgin Olive Oil (EVOO), Physical Exercise Program
Keywords
Mediterranean Diet, Olive Oil, Physical Exercise, Autoimmune Diseases, Systemic Lupus Erythematosus, Microbiome, Epigenetcis
Medical subject headings
Lupus Erythematosus, Systemic, Motor Activity, Autoimmune Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Extra Virgin Olive Oil (EVOO)Dietary supplement

    Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.

  • Physical Exercise ProgramBehavioural

    Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.

Study groups in NCT05261529
Study groupRoleWhat they receive
Control GroupNo interventionControl Group with 30 patients diagnosed with SLE following their normal lifestyle in terms of dietary intake and physical exercise.
Oil GroupExperimentalGroup with 30 patients diagnosed with SLE that add to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, without changing their lifestyle in terms of physical exercise.
Receives: Dietary Supplement: Extra Virgin Olive Oil (EVOO)
Oil + Exercise GroupExperimentalGroup with 30 patients diagnosed with SLE that besides adding to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, will follow a physical exercise multimodal program the 12 last weeks.
Receives: Dietary Supplement: Extra Virgin Olive Oil (EVOO); Behavioral: Physical Exercise Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SLEDAI Systemic Lupus Erythematosus Disease Activity Index

    SLE-specific index that assess disease activity through a combination of data from clinical records, physical examination, organ-specific functional tests and serological studies.

    Measured: Participants will be followed over 24 weeks.

Secondary outcomes (45)
  1. Cumulative manifestations

    All the manifestations and complications that patients go through or appear during the intervention, recorded by interview with clinicians.

    Measured: Participants will be followed over 24 weeks.

  2. SLICC/ACR (Systemic Lupus International Collaborating clinics/American College of Rheumatology) Damage Index for Systemic Lupus Erythematosus.

    Index developed to quantify damage that has occurred since onset of lupus, correlates with mortality. Score and clinical relevance registered by interview with clinicians.

    Measured: Participants will be followed over 24 weeks.

  3. Pharmacological prescription

    All the medicines that the patients are taking, start to take, o stop taking during the intervention, registered by interview with clinicians.

    Measured: Participants will be followed over 24 weeks.

  4. Glucose level

    Glucose will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  5. Urea level

    Urea will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  6. Creatinine level

    Creatinine will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  7. Lipid profile analysis

    Lipid profile will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  8. Creatine Kinase concentration

    Creatine Kinase (CK) will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  9. Hemoglobin concentration

    Hemoglobin (Hb) will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  10. Number of lymphocytes

    Number of lymphocytes will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  11. Number of platelets

    Number of platelets will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  12. Number of leukocytes

    Number of leukocytes will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  13. Inflammation

    C-Reactive Protein (CRP) will be analyzed trough blood test.

    Measured: Participants will be followed over 24 weeks.

  14. Anti phospholipid antibodies concentration

    Autoimmunity Anti phospholipid antibodies parameter will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  15. Double-stranded anti-DNA antibodies concentration

    Autoimmunity Double-stranded anti-DNA antibodies parameter will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  16. Complement fraction C3 concentration

    Autoimmunity Complement fraction C3 parameter will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  17. Complement fraction C4 concentration

    Autoimmunity Complement fraction C4 parameter will be analyzed through blood test.

    Measured: Participants will be followed over 24 weeks.

  18. Cardiorespiratory Fitness

    Evaluated by Treadmill Ergometric test.

    Measured: Participants will be followed over 24 weeks.

  19. Functional capacity

    Evaluated by the 6-Minute walking test.

    Measured: Participants will be followed over 24 weeks.

  20. Hight

    In centimeters; will be evaluated using a measuring tape.

    Measured: Participants will be followed over 24 weeks.

  21. Weight

    In kilograms; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  22. Skeletal Muscle Mass

    In kilograms; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  23. Body Fat Mass

    In kilograms; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  24. Body Mass Index

    Weight and height will be combined to report Body Mass Index (BMI) in kg/m^2

    Measured: Participants will be followed over 24 weeks.

  25. Body Fat Index

    In %; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  26. Waist-to-hip ratio in centimeters

    In centimeters; waist circumference and hip circumference measures will be combined to calculate waist-to-hip ratio (WHR).

    Measured: Participants will be followed over 24 weeks.

  27. Obesity degree

    In %; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  28. Body Cell Mass

    In kilograms; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  29. Bone Mineral Content

    In kilograms; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  30. Basal Metabolic Rate

    In kilocalories; will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  31. Visceral Fat Area

    In cm^2; Visceral Fat Area (AVG) will be evaluated using an Inbody.

    Measured: Participants will be followed over 24 weeks.

  32. Bone density

    Evaluated by densitometry.

    Measured: Participants will be followed over 24 weeks.

  33. Human Vascular Cell Adhesion Molecule-1 concentration

    VCAM-1 endothelial biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  34. Intercellular Adhesion Molecule-1concentration

    ICAM-1 endothelial biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  35. E-Selectin concentration

    E-Selectin endothelial biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  36. Super Oxide Dismutase concentration

    Oxidative Stress SOD biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  37. Glutathione concentration

    Oxidative Stress GSH biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  38. Total Antioxidant Capacity concentration

    Oxidative Stress TAC biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  39. Thiobarbituric Acid Reactive Substances concentration

    Oxidative Stress TBARS biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  40. Malondialdehyde concentration

    Oxidative Stress MDA biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  41. Advanced Oxidation Protein Products concentration

    Oxidative Stress AOPP biomarker will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  42. Total proteins concentration

    Oxidative Stress total proteins biomarker, understood as the concentration of proteins in a sample, will be assessed by blood test.

    Measured: Participants will be followed over 24 weeks.

  43. Endothelial Function

    Several endothelial function parameters such are arterial pulse wave velocity, AIX index, ABI will be evaluated using arteriography.

    Measured: Participants will be followed over 24 weeks.

  44. miRNA expression profile quantification

    Collection of blood samples in Tempus tubes for subsequent analysis of miRNA expression profile by massive sequencing with specific equipment.

    Measured: Participants will be followed over 24 weeks.

  45. Microbiome characteristics analysis

    Microbiome study by collecting fecal samples.

    Measured: Participants will be followed over 24 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2022
  2. Study start3 Nov 2021
  3. Primary completion30 Dec 2022 (estimated)
  4. Study completion30 Jun 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Three-arm prospective randomized controlled 24-week clinical trial of patients diagnosed with SLE.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05261529
Sponsor's protocol ID
2099-N-21
Acronym
EFINUTRILES
Status last verified
Dec 2022
First submitted
8 Feb 2022
Last updated
20 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Pocovi-Gerardino G, Correa-Rodriguez M, Callejas-Rubio JL, Rios-Fernandez R, Martin-Amada M, Cruz-Caparros MG, Rueda-Medina B, Ortego-Centeno N. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology (Oxford). 2021 Jan 5;60(1):160-169. doi: 10.1093/rheumatology/keaa210.

    PubMed 32594173
  • Gil-Gutierrez R, Medina-Martinez I, Quesada-Caballero M, de la Hera-Fernandez FJ, Zamora-Pasadas M, Cantarero-Villanueva I, Albendin-Garcia L, Parola V, Rueda-Medina B, Correa-Rodriguez M. EFINUTRILES Study: Integrative Extra Virgin Olive Oil and Multimodal Lifestyle Interventions for Cardiovascular Health and SLE Management. Nutrients. 2025 Mar 19;17(6):1076. doi: 10.3390/nu17061076.

    PubMed 40292522

Questions about this trial

What is this clinical trial studying?

A study testing Extra Virgin Olive Oil (EVOO) and Physical Exercise Program in people with Lupus Erythematosus, Systemic, run by Universidad de Granada at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact María Corea Rodríguez, Professor (958243494 ext. +34, macoro@ugr.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SLEDAI Systemic Lupus Erythematosus Disease Activity Index (time frame: Participants will be followed over 24 weeks.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05261529, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in